vs

Side-by-side financial comparison of CEMTREX INC (CETX) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $16.1M, roughly 1.2× CEMTREX INC). CEMTREX INC runs the higher net margin — -127.4% vs -177.4%, a 50.0% gap on every dollar of revenue. On growth, CEMTREX INC posted the faster year-over-year revenue change (17.4% vs -11.5%). CEMTREX INC produced more free cash flow last quarter ($-1.1M vs $-23.1M). Over the past eight quarters, CEMTREX INC's revenue compounded faster (-3.0% CAGR vs -12.2%).

Cemtrex Inc is a diversified industrial technology firm developing IoT-enabled industrial automation solutions, environmental monitoring systems, and digital workplace tools. Its core clients are from manufacturing, industrial and commercial sectors, mainly in North America and European markets.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

CETX vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.2× larger
LAB
$19.6M
$16.1M
CETX
Growing faster (revenue YoY)
CETX
CETX
+28.9% gap
CETX
17.4%
-11.5%
LAB
Higher net margin
CETX
CETX
50.0% more per $
CETX
-127.4%
-177.4%
LAB
More free cash flow
CETX
CETX
$22.0M more FCF
CETX
$-1.1M
$-23.1M
LAB
Faster 2-yr revenue CAGR
CETX
CETX
Annualised
CETX
-3.0%
-12.2%
LAB

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
CETX
CETX
LAB
LAB
Revenue
$16.1M
$19.6M
Net Profit
$-20.6M
$-34.7M
Gross Margin
34.8%
48.5%
Operating Margin
-17.4%
-168.5%
Net Margin
-127.4%
-177.4%
Revenue YoY
17.4%
-11.5%
Net Profit YoY
28.5%
-28.8%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CETX
CETX
LAB
LAB
Q4 25
$16.1M
Q3 25
$18.5M
$19.6M
Q2 25
$17.0M
$21.8M
Q1 25
$27.3M
$40.8M
Q4 24
$13.7M
Q3 24
$18.1M
$22.1M
Q2 24
$14.7M
$22.5M
Q1 24
$17.2M
$45.5M
Net Profit
CETX
CETX
LAB
LAB
Q4 25
$-20.6M
Q3 25
$-3.4M
$-34.7M
Q2 25
$-4.5M
$-33.5M
Q1 25
$8.4M
$-26.0M
Q4 24
$-28.8M
Q3 24
$4.4M
$-26.9M
Q2 24
$-9.0M
$-45.7M
Q1 24
$-1.5M
$-32.2M
Gross Margin
CETX
CETX
LAB
LAB
Q4 25
34.8%
Q3 25
38.0%
48.5%
Q2 25
43.4%
48.8%
Q1 25
44.6%
48.4%
Q4 24
41.5%
Q3 24
41.8%
54.9%
Q2 24
40.0%
46.1%
Q1 24
40.4%
53.1%
Operating Margin
CETX
CETX
LAB
LAB
Q4 25
-17.4%
Q3 25
-6.4%
-168.5%
Q2 25
-3.8%
-118.1%
Q1 25
16.9%
-80.8%
Q4 24
-16.6%
Q3 24
-1.8%
-120.9%
Q2 24
-21.6%
-134.5%
Q1 24
-6.0%
-132.2%
Net Margin
CETX
CETX
LAB
LAB
Q4 25
-127.4%
Q3 25
-18.1%
-177.4%
Q2 25
-26.8%
-153.7%
Q1 25
30.8%
-63.8%
Q4 24
-209.3%
Q3 24
24.1%
-122.0%
Q2 24
-61.2%
-203.3%
Q1 24
-8.6%
-70.6%
EPS (diluted)
CETX
CETX
LAB
LAB
Q4 25
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q4 24
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CETX
CETX
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$20.5M
$129.4M
Total DebtLower is stronger
$12.8M
Stockholders' EquityBook value
$29.1M
$399.7M
Total Assets
$60.3M
$539.6M
Debt / EquityLower = less leverage
0.44×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CETX
CETX
LAB
LAB
Q4 25
$20.5M
Q3 25
$5.0M
$129.4M
Q2 25
$7.0M
$158.6M
Q1 25
$4.5M
$150.9M
Q4 24
$4.2M
Q3 24
$3.9M
$210.6M
Q2 24
$6.5M
$269.8M
Q1 24
$2.9M
$287.1M
Total Debt
CETX
CETX
LAB
LAB
Q4 25
$12.8M
Q3 25
$13.5M
Q2 25
$18.3M
Q1 25
$18.9M
Q4 24
$18.7M
Q3 24
$18.0M
$55.2M
Q2 24
$55.1M
Q1 24
$21.6M
$55.0M
Stockholders' Equity
CETX
CETX
LAB
LAB
Q4 25
$29.1M
Q3 25
$8.7M
$399.7M
Q2 25
$3.6M
$424.5M
Q1 25
$6.4M
$454.6M
Q4 24
$-1.6M
Q3 24
$4.7M
$489.3M
Q2 24
$48.0K
$510.3M
Q1 24
$4.7M
$577.3M
Total Assets
CETX
CETX
LAB
LAB
Q4 25
$60.3M
Q3 25
$47.8M
$539.6M
Q2 25
$47.0M
$557.0M
Q1 25
$46.2M
$579.6M
Q4 24
$46.7M
Q3 24
$44.1M
$681.5M
Q2 24
$43.8M
$708.7M
Q1 24
$47.2M
$777.7M
Debt / Equity
CETX
CETX
LAB
LAB
Q4 25
0.44×
Q3 25
1.55×
Q2 25
5.07×
Q1 25
2.94×
Q4 24
Q3 24
3.82×
0.11×
Q2 24
0.11×
Q1 24
4.60×
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CETX
CETX
LAB
LAB
Operating Cash FlowLast quarter
$-891.9K
$-22.2M
Free Cash FlowOCF − Capex
$-1.1M
$-23.1M
FCF MarginFCF / Revenue
-6.7%
-118.1%
Capex IntensityCapex / Revenue
1.1%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-721.5K
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CETX
CETX
LAB
LAB
Q4 25
$-891.9K
Q3 25
$-3.3M
$-22.2M
Q2 25
$1.8M
$-20.7M
Q1 25
$2.8M
$-30.3M
Q4 24
$-1.2M
Q3 24
$-1.9M
$-27.9M
Q2 24
$675.8K
$-39.0M
Q1 24
$386.8K
$-62.5M
Free Cash Flow
CETX
CETX
LAB
LAB
Q4 25
$-1.1M
Q3 25
$-3.7M
$-23.1M
Q2 25
$1.7M
$-22.6M
Q1 25
$2.4M
$-35.3M
Q4 24
$-2.1M
Q3 24
$-2.7M
$-30.1M
Q2 24
$601.7K
$-41.0M
Q1 24
$322.2K
$-63.3M
FCF Margin
CETX
CETX
LAB
LAB
Q4 25
-6.7%
Q3 25
-20.2%
-118.1%
Q2 25
10.2%
-103.6%
Q1 25
8.7%
-86.6%
Q4 24
-15.5%
Q3 24
-15.1%
-136.4%
Q2 24
4.1%
-182.2%
Q1 24
1.9%
-138.9%
Capex Intensity
CETX
CETX
LAB
LAB
Q4 25
1.1%
Q3 25
2.7%
4.5%
Q2 25
0.4%
8.7%
Q1 25
1.6%
12.4%
Q4 24
6.7%
Q3 24
4.8%
10.2%
Q2 24
0.5%
8.6%
Q1 24
0.4%
1.7%
Cash Conversion
CETX
CETX
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
0.33×
Q4 24
Q3 24
-0.43×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CETX
CETX

Industrial Services$10.6M66%
Security$5.5M34%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons